Returning as the largest and definitive ADC congress, the 17th World ADC San Diego is THE one-stop bioconjugate shop, bringing together the global ADC community for an unparalleled amalgamation of case studies, development trends and networking opportunities to forge ADC innovation into differentiated, early-line patient outcomes.
Uniting 1,300 industry senior enthusiasts from biopharma, innovative start-ups, leading service providers and academic, physician and regulator KOLs, World ADC San Diego is the place to discuss, debate and advance the future of ADC development.
Featuring 170+ senior presenters, a snapshot of the 2026 speaker faculty includes:
- Suzanne Edavettal, Vice President, Research & Head, Protein Therapeutics, Amgen
- Vinod Bulusu, Executive Director, Product Stewardship Lead, AstraZeneca
- Giorgia Vicentini, Vice President, Global Program Lead, Oncology, Bristol Myers Squibb
- Ronald Fleming, Executive Director, Clinical Development, Daiichi Sankyo
- Gail Lewis, Distinguished Scientist, Discovery Oncology, Genentech
- Min Hu, Senior Vice President, Discovery, Innovent Biologics
- Bob Lutz, Chief Scientific Officer, Iksuda Therapeutics
- Jeffrey Settleman, Chief Scientific Officer, Oncology R&D, Pfizer
- Dominik Schumacher, Chief Executive Officer, Tubulis
- Rita Nanda, Associate Professor, Medicine & Director, Breast Oncology, Section of Hematology/Oncology, University of Chicago
View the full list of speaking companies: https://ter.li/xsz013cs
If you want to stay competitive in the field, you cannot miss World ADC San Diego to de-risk future ADC development and push ADCs to earlier-line oncology treatments.